BRCA1 and ovarian cancer: However, only 15–20% of the cancers have a BRCA1/2 mutation (germline or somatic) [6], and therefore response to chemotherapy in the remaining percentage of patients with ovarian cancer is not subject to prediction on the basis of that genomic marker.